Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rybak

Showing results (131-140 of 531) with videos related to

Pageof 54
Sort By:
Clinical Pharmacy|February 1, 1989
Enoxacin: a new fluoroquinoloneL A Jaber, E M Bailey, M J Rybak
Journal of the American Chemical Society|October 17, 2024
Dinickel-Catalyzed N=N Coupling Reactions for the Synthesis of Hindered AzoarenesChristopher J Rybak, Chengyi Fan, Parijat Sharma, et al.
Infectious Diseases and Therapy|February 3, 2016
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive InfectionsKarrine D Brade, Jeffrey M Rybak, Michael J Rybak
Pharmacotherapy|October 27, 2015
Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive InfectionsKarrine D Roberts, Rand M Sulaiman, Michael J Rybak
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 9, 2019
Delafloxacin in Acute Bacterial Skin and Skin Structure InfectionsG Ralph Corey, Jamie A McKinnell, Michael J Rybak
Drug Intelligence & Clinical Pharmacy|June 1, 1984
Sensitivity testing and the inoculum effectS R Erickson, S A Hunt, M J Rybak
Antimicrobial Agents and Chemotherapy|January 27, 2006
Pulsatile delivery of clarithromycin alone or in combination with amoxicillin against Streptococcus pneumoniaeKimberly D Leuthner, Chrissy M Cheung, Michael J Rybak
The Annals of Pharmacotherapy|May 1, 1994
Oral treatment of gonorrhea and chlamydiaK A Loughlin, C M Bakst, M J Rybak
Antimicrobial Agents and Chemotherapy|September 1, 1993
Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro modelB J McGrath, K C Lamp, M J Rybak
Antimicrobial Agents and Chemotherapy|May 17, 2001
Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniaeE A Coyle, G W Kaatz, M J Rybak
Pageof 54

Showing results (131-140 of 531) with videos related to

Sort By:
Pageof 54
Clinical Pharmacy|February 1, 1989
Enoxacin: a new fluoroquinoloneL A Jaber, E M Bailey, M J Rybak
Journal of the American Chemical Society|October 17, 2024
Dinickel-Catalyzed N=N Coupling Reactions for the Synthesis of Hindered AzoarenesChristopher J Rybak, Chengyi Fan, Parijat Sharma, et al.
Infectious Diseases and Therapy|February 3, 2016
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive InfectionsKarrine D Brade, Jeffrey M Rybak, Michael J Rybak
Pharmacotherapy|October 27, 2015
Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive InfectionsKarrine D Roberts, Rand M Sulaiman, Michael J Rybak
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 9, 2019
Delafloxacin in Acute Bacterial Skin and Skin Structure InfectionsG Ralph Corey, Jamie A McKinnell, Michael J Rybak
Drug Intelligence & Clinical Pharmacy|June 1, 1984
Sensitivity testing and the inoculum effectS R Erickson, S A Hunt, M J Rybak
Antimicrobial Agents and Chemotherapy|January 27, 2006
Pulsatile delivery of clarithromycin alone or in combination with amoxicillin against Streptococcus pneumoniaeKimberly D Leuthner, Chrissy M Cheung, Michael J Rybak
The Annals of Pharmacotherapy|May 1, 1994
Oral treatment of gonorrhea and chlamydiaK A Loughlin, C M Bakst, M J Rybak
Antimicrobial Agents and Chemotherapy|September 1, 1993
Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro modelB J McGrath, K C Lamp, M J Rybak
Antimicrobial Agents and Chemotherapy|May 17, 2001
Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniaeE A Coyle, G W Kaatz, M J Rybak
Pageof 54